Bio-Techne (TECH) Akcija Kursas
Bio-Techne Kursas
Pajamos augo 9,3 % per metus per pastaruosius 19 metus iki 1,22 mlrd. USD. Pelnas akcijai augo 4,1 % per metus per pastaruosius 19 metus. Bio-Techne grynoji marža dabar yra 15,0 %, sumažėjo nuo 24,6 % prieš kelerius metus. Bio-Techne šiuo metu siūlo apie 0,44 % dividendo pajamingumą. Išmokų koeficientas yra apie 40 % pelno. Dividendas augo 9,5 % per metus per pastaruosius 18 metus. Analitikų tikslinės kainos mediana yra 73,00 USD, t. y. virš dabartinę kainą 0,7 %. Iš 22 analitikų 7 rekomenduoja pirkti — bendras konsensusas yra Laikyti.
Bio-Techne akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Bio-Techne akcija ir akcijų analizė
Dažnai užduodami klausimai apie Bio-Techne akciją
Bio-Techne Corp's business model revolves around providing innovative life science tools and solutions to researchers worldwide. The company focuses on developing and manufacturing high-quality reagents, assays, and instruments used in biomedical research, clinical diagnostics, and pharmaceutical development. With a diverse portfolio, Bio-Techne offers products for gene expression analysis, protein analysis, cell imaging, and stem cell research. Their advanced technologies and expertise enable scientists to accelerate discoveries and enhance their understanding of diseases, ultimately aiding in the development of new therapies. Bio-Techne Corp strives to be at the forefront of scientific advancements by continually investing in research and development initiatives.
Bio-Techne Corp primarily operates in the biotechnology and life sciences industries. Its extensive product portfolio includes cutting-edge solutions for research and diagnostics, spanning the fields of pharmaceuticals, clinical applications, bioprocessing, and academia. With a focus on developing innovative technologies, Bio-Techne Corp delivers products and services that support advancements in areas such as cancer research, stem cell research, immunology, neuroscience, and genetic analysis. As a leading player in these sectors, Bio-Techne Corp continues to make significant contributions to the scientific community and drive progress in the biotechnology field.
Some of the main competitors of Bio-Techne Corp in the market include Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies.
Bio-Techne Corp, formerly known as Techne Corporation, is a leading global life sciences company. Established in 1976, Bio-Techne has a rich history of innovation and scientific discovery. The company develops and manufactures a wide range of cutting-edge products and solutions for the biotechnology and clinical research industries. With a strong focus on research and development, Bio-Techne has consistently brought forth groundbreaking technologies and advanced tools, revolutionizing the understanding and treatment of diseases. Today, Bio-Techne Corp remains at the forefront of the life sciences industry, delivering high-quality products and driving advancements in scientific research worldwide.
Bio-Techne Corp has achieved several significant milestones. The company has successfully expanded its product portfolio, offering a wide range of innovative solutions in life sciences research and diagnostics. Bio-Techne Corp has also witnessed strong financial performance, consistently delivering impressive revenue growth over the years. Moreover, the company has made strategic acquisitions to enhance its capabilities and market presence. With a focus on advanced technologies and a commitment to innovation, Bio-Techne Corp continues to contribute to scientific advancements and improve healthcare outcomes globally.
Bio-Techne Corp is primarily present in various countries and regions worldwide. The company has a widespread global presence, with significant operations and a strong market presence in North America, Europe, and Asia-Pacific. This enables Bio-Techne Corp to serve a diverse customer base and tap into multiple international markets. Along with its headquarters in the United States, Bio-Techne Corp has strategic offices, production facilities, and distribution networks across key countries and regions globally. This expansive global footprint allows the company to effectively deliver its innovative biotechnology solutions and services to customers around the world.
Bio-Techne Corp is a leading global provider of life science products and solutions. The company values innovation, scientific excellence, and customer-centricity. Bio-Techne Corp's corporate philosophy revolves around advancing scientific discoveries and improving human health. With a strong commitment to research and development, Bio-Techne Corp focuses on providing cutting-edge tools and technologies to support the life science community. By fostering collaboration and investing in breakthrough technologies, the company aims to accelerate scientific progress and enable researchers to make significant contributions in the fields of genomics, proteomics, and cell biology. Overall, Bio-Techne Corp is dedicated to driving innovation and making a positive impact in the life science industry.
Analitikai šiuo metu nustato vidutinę Bio-Techne akcijos tikslinę kainą 65,78 USD (mediana: 73,00 USD), t. y. −9,3 % palyginti su paskutine kaina. Konsensusas pagrįstas 22 analitikų reitingais.
22 analitikai šiuo metu vertina Bio-Techne akciją: 7 rekomenduoja pirkti, 15 laikyti ir 0 parduoti.
Pagal dabartinį kursą Bio-Techne akcija kainuoja 64,66 EUR (72,52 USD).
Bio-Techne akcija (TECH) kotiruojama 4 biržose, įskaitant: NASDAQ (TECH), Frankfurt (TE1.F), München (TE1.MU), Düsseldorf (TE1.DU).
Bio-Techne Corp is a leading provider of innovative products for the biotechnology and clinical diagnostics industry. The company offers a wide range of products and services for protein research, cell analysis, microscopy, genomics, and clinical diagnostics. Protein research: Bio-Techne offers proteins, antibodies, reagents, and instruments for signal pathway research, protein expression, and function. Well-known brands in this field include R&D Systems, Novus Biologicals, Tocris, and ProteinSimple. Cell analysis: For cell analysis, Bio-Techne provides a wide range of products including cell analysis devices, reagents, and instruments for flow cytometry, cell culture, and microscopy. BioLegend is the leading brand for cell analysis products from Bio-Techne. Microscopy: Bio-Techne also offers a wide range of microscopy products for cell and tissue analysis. This includes endoscopes, cameras, microscopes, imaging software, and accessories. Brands in this field include Nikon Instruments, Zeiss, and Lumera. Genomics: Bio-Techne's genomics offering includes custom gene synthesis, antisense oligonucleotides, miRNA inhibitors, as well as PCR, qPCR, and sequencing kits and reagents. The company also provides comprehensive genomics services including analysis, sequencing, and data analysis. Clinical diagnostics: Bio-Techne provides solutions for clinical diagnostics, including IVD reagents, custom biomarker development and services, immunohistochemistry test systems, as well as devices and instruments for clinical sample submission. Brands in this field include R&D Systems, Novus Biologicals, and Exosome Diagnostics. Summary: Overall, Bio-Techne Corp offers a wide range of solutions for the biotechnology and clinical diagnostics industry. With its leading brands and extensive range of products and services, the company has established itself as a key player in this field. Through continuous product and service development and innovation, Bio-Techne is able to maintain its market share and further expand its business in various niche markets.
pelnas Bio-Techne yra 1,22 mlrd. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
grynasis pelnas Bio-Techne yra 181,86 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Bio-Techne šiuo metu yra 62,61. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Bio-Techne akcijos vertę.
Kainų ir pardavimų santykis (KUV) Bio-Techne šiuo metu yra 9,37. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Bio-Techne akcijos įvertinimo metrika.
Eulerpool kokybės balas Bio-Techne yra 4/10.
Bio-Techne ISIN yra US09073M1045. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Bio-Techne WKN yra A12ENG. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Bio-Techne prekybos žymė yra TECH. Ši biržos žymė naudojama Bio-Techne akcijoms prekiauti biržoje.
Bio-Techne akcija
Bio-Techne Pagrindiniai konkurentai
Bio-Techne Biržos simbolis
Bio-Techne FIGI
Visos Bio-Techne pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Bio-Techne akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Bio-Techne. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: